Pharmafile Logo

News and Press Releases

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31 March 2026 -- Nijmegen, Netherlands -- Symeres, a leading CRDMO for drug discovery and development has partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2026

BioCurie to Receive Up to $9.3 Million ARPA-H Award to Build AI Platform for Scalable Gene Therapy Manufacturing

12 March 2026 -- Delaware and Massachuetts, US -- BioCurie, a TechBio company building an AI-driven digital platform for cell and gene therapy manufacturing, was awarded up to $9.3 million...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: March 12, 2026

BioCurie
contact@biocurie.com
112 South French Street Wilmington, Delaware 19801 USA

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

27 January 2026 -- Illinois, US -- Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 27, 2026

Tempus
support@tempus.com
600 W Chicago Ave. Ste 510, Chicago, IL 60654

Automata and CellVoyant Announce Strategic Partnership to Deliver AI-Powered Closed-Loop Cell Culture Workflows

13 January 2026 -- California, US -- Automata, a leading provider of modular, fully-integrated and AI-ready lab automation, and CellVoyant, a pioneer in AI foundation models for ‘live’ label-free cell...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2026

CellVoyant
info@cellvoyant.com
Origin Workspace 40 Berkeley Square, Bristol BS8 1HP

Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities

The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2025

PrecisionLife
info@precisionlife.com
8b Bankside Hanborough Business Park Oxford, OX29 8LJ

Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025

Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges 27 October 2025 -- Frankfurt, Germany -- Thermo Fisher Scientific...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics

Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI design and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Nabla Bio
bd@nabla.bio
Riverside Technology Center
 840 Memorial Dr
 Cambridge, MA 02139

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Relief Therapeutics
contact@relieftherapeutics.com
Avenue de Sécheron 15 1202 Geneva Switzerland

EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology

4 August 2025 -- Illinois, US -- EVERSANA, a leading provider of commercialization services to the global life sciences industry, today launched a groundbreaking pharmaceutical marketing AI agency running on...

Category: Other, Pharmaceutical
Posted: August 4, 2025

Eversana
404 S. Wells Street, Chicago, IL 60607

HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure

7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025

Heartbeat.Bio
office@heartbeat.bio
Vienna Biocenter 6 Dr. Bohr-Gasse 7 A-1030 Vienna Austria

TriloDocs Ltd Joins Genactis Group

16 March 2025 -- London, UK -- We're excited to share some important news! TriloDocs has recently been acquired by Genactis: a global leader in healthcare research and technology. This...

Category: Clinical Trials, Other, Pharmaceutical
Posted: April 16, 2025

TriloDocs
contact@trilodocs.com
25 WILTON Road | LONDON | UNITED KINGDOM | SW1V 1LW

Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection

Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025

Phesi
info@phesi.com
East Lyme, Connecticut, US

ELRIG Announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025

Therapeutic Oligonucleotides 2025: Drugging the Undruggable takes place at AstraZeneca in Gothenburg, Sweden from 14–15 May 25 March 2025 -- Cambridge, UK -- ELRIG, a not-for-profit, volunteer-led organisation for the drug...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025

European Laboratory Research and Innovation Group (ELRIG)
info@elrig.org
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025

Owkin
https://www.owkin.com/
14/16 Bd Poissonnière, 75009 Paris